Literature DB >> 1618671

The use of 3-D dose volume analysis to predict radiation hepatitis.

T S Lawrence1, R K Ten Haken, M L Kessler, J M Robertson, J T Lyman, M L Lavigne, M B Brown, D J DuRoss, J C Andrews, W D Ensminger.   

Abstract

Although it is well known that the tolerance of the liver to external beam irradiation depends on the volume of liver irradiated, few data exist which quantify this dependence. Therefore, a review was carried out of our clinical trial for the treatment of intrahepatic malignancies in which the dose of radiation delivered depended on the volume of normal liver treated. Three dimensional treatment planning using dose-volume histogram analysis of the normal liver was used for all patients. Nine of the 79 patients treated developed clinical radiation hepatitis. None of the patient related variables assessed were associated with radiation hepatitis. All patients who developed radiation hepatitis received whole liver irradiation, as all or part of their treatment, which produced a mean dose greater than or equal to 37 Gy. Dose volume histograms were used to calculate normal tissue complication probabilities based on parameters derived from the literature. The risk of complication was greatly overestimated among patients receiving a high dose of radiation to part of the liver without whole liver treatment. An estimation of model parameters based on the clinical results indicated a larger magnitude for the "volume effect parameter" than the literature estimate (n = 0.69 +/- 0.05 vs 0.32; p less than 0.001). Computation of the normal tissue complication probabilities using the larger value of n produced a good description of the observed risk of radiation hepatitis. These findings suggest that dose volume histogram analysis can be used to quantify the tolerance of the liver to radiation. The predictive value of this parameterization of the normal tissue complication probability model will need to be tested with liver tolerance and dose volume histogram data from an independent clinical trial.

Entities:  

Mesh:

Year:  1992        PMID: 1618671     DOI: 10.1016/0360-3016(92)90651-w

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  57 in total

1.  RapidArc vs intensity-modulated radiation therapy for hepatocellular carcinoma: a comparative planning study.

Authors:  J M Park; K Kim; E K Chie; C H Choi; S J Ye; S W Ha
Journal:  Br J Radiol       Date:  2012-07       Impact factor: 3.039

Review 2.  [Radiotherapy of hepatic metastases].

Authors:  S E Combs; K K Herfarth; D Habermehl; J Debus
Journal:  Chirurg       Date:  2010-06       Impact factor: 0.955

Review 3.  Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus.

Authors:  Masami Minagawa; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

4.  Validation of the liver mean dose in terms of the biological effective dose for the prevention of radiation-induced liver damage.

Authors:  Hiroshi Doi; Norihisa Masai; Kenji Uemoto; Osamu Suzuki; Hiroya Shiomi; Daisaku Tatsumi; Ryoong-Jin Oh
Journal:  Rep Pract Oncol Radiother       Date:  2017-05-05

5.  Adaptive trial of personalized radiotherapy for intrahepatic cancer.

Authors:  Daniel Normolle; Charlie Pan; Edgar Ben-Josef; Theodore Lawrence
Journal:  Per Med       Date:  2010       Impact factor: 2.512

6.  Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel.

Authors:  Bertrand Janne d'Othée; Constantinos T Sofocleous; Nader Hanna; Robert J Lewandowski; Michael C Soulen; Jean-Nicolas Vauthey; Steven J Cohen; Alan P Venook; Matthew S Johnson; Andrew S Kennedy; Ravi Murthy; Jean-Francois Geschwind; Stephen T Kee
Journal:  J Vasc Interv Radiol       Date:  2012-02       Impact factor: 3.464

Review 7.  Radiation dose escalation for locally advanced unresectable intrahepatic and extrahepatic cholangiocarcinoma.

Authors:  Santiago Avila; Danyal A Smani; Eugene J Koay
Journal:  Chin Clin Oncol       Date:  2019-12-19

8.  Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Sung Uk Lee; Joong-Won Park; Tae Hyun Kim; Yeon-Joo Kim; Sang Myung Woo; Young-Hwan Koh; Woo Jin Lee; Sang-Jae Park; Dae Yong Kim; Chang-Min Kim
Journal:  Strahlenther Onkol       Date:  2014-03-04       Impact factor: 3.621

Review 9.  Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance.

Authors:  Christopher H Crane; Eugene J Koay
Journal:  Cancer       Date:  2016-03-07       Impact factor: 6.860

Review 10.  Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma.

Authors:  Chihwan Choi; Gi Hong Choi; Tae Hyun Kim; Masatoshi Tanaka; Mao-Bin Meng; Jinsil Seong
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.